Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells

Annals of Surgery

Volumn 260, Issue 1, 2014, Pages 72-80

  Bandla, Santhoshi ^a   Peters, Jeffrey H ^a   Ruff, David ^b   Chen, Shiaw Min ^b   Li, Chieh Yuan ^b   Song, Kunchang ^a   Thoms, Kimberly ^a   Litle, Virginia R ^f   Watson, Thomas ^a   Chapurin, Nikita ^a   Lada, Michal ^a   Pennathur, Arjun ^e   Luketich, James D ^e   Peterson, Derick ^a   Dulak, Austin ^c   Lin, Lin ^d   Bass, Adam ^c   Beer, David G ^d   Godfrey, Tony E ^f,g   Zhou, Zhongren ^a,h  

^a STRONG MEMORIAL HOSPITAL   (United States)

^b Life Technologies Corporation   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f BOSTON MEDICAL CENTER   (United States)

^g BOSTON UNIVERSITY   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Barrett's esophagus; DNA copy number alterations; esophageal metaplasia; mutation; surveillance

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

BARRETT ESOPHAGUS; CANCER RISK; CHROMOSOME 8; CLINICAL ARTICLE; COLUMNAR LINED ESOPHAGUS TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS; ESOPHAGUS BIOPSY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC DISORDER; GOBLET CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE METAPLASIA; MALE; METAPLASIA; MICROARRAY ANALYSIS; MUTATION; NONGOBLET CELL METAPLASIA; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; BIOPSY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENES, P16; GOBLET CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; METAPLASIA; MUTATION; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES;

EID: 84902251113     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000424     Document Type: Review

References (35)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
2. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184-1187.
3. Reid BJ, Li X, Galipeau PC, et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10:87-101.
4. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence ofBarrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-1831.
5. Jankowski J, Barr H, Wang K, et al. Diagnosis and management of Barrett's oesophagus. BMJ. 2010;341:c4551.
6. Jankowski JA, Harrison RF, Perry I, et al. Barrett's metaplasia. Lancet. 2000;356:2079-2085.
7. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl JMed. 2011;365:1375-1383.
8. Bhat S, Coleman HG, Yousef F, et al. Risk ofmalignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049-1057.
9. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012;61:970-976.
10. American Gastroenterological Association Spechler SJ, Sharma P, et al.American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140:1084-1091.
11. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of G. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788-797.
12. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut. 2006;55:442.
13. Kelty CJ, Gough MD, VanWyk Q, et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42:1271-1274.
14. Gatenby PA, Ramus JR, Caygill CP, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43:524-530.
15. Inadomi JM. Surveillance in Barrett's esophagus: a failed premise. Keio JMed. 2009;58:12-18.
16. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176-186.
17. Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus. 2007;20:36-41.
18. Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead? Am J Gastroenterol. 2009;104:2588-2594.
19. Ong CA, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol. 2010;16:5669-5681.
20. Li X, Galipeau PC, Sanchez CA, et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila). 2008;1:413-423.
21. Lai LA, Paulson TG, Li X, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer. 2007;46:532-542.
22. Paulson TG, Maley CC, Li X, et al. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15:3305-3314.
23. Paulson TG, Galipeau PC, Xu L, et al. p16 mutation spectrum in the premalignant condition Barrett's esophagus. PLoS One. 2008;3:e3809.
24. Reid BJ. Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark. 2010;9:307-324.
25. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cellcontaining epithelium. Am J Gastroenterol. 2009;104:816-824.
26. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478-486.
27. Rothberg JM, HinzW, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475:348-352.
28. Dulak AM, Schumacher S, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012;72:4383-4393.
29. Lai LA, Kostadinov R, Barrett MT, et al. Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res. 2010;8:1084-1094.
30. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305:525-528.
31. Merlo LM, Shah NA, Li X, et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2010;3:1388-1397.
32. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468-473.
33. Chaves P, Crespo M, Ribeiro C, et al. Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved. Mod Pathol. 2007;20:788-796.
34. Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med. 2011;5:397-404.
35. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.